Reducing the rise in type 2 diabetes

The York and Humber Public Health Observatory reports that 4.7% of the population now have diabetes, of which 92% (4.3% of the population) have type 2 diabetes. The diagnosed prevalence has doubled between 1994 and 2003. The increasing number of people with type 2 diabetes reflects several factors: an ageing population; a true increase in prevalence, related to increased prevalence of overweight and obesity; decreasing physical activity; better survival of those with diabetes due to improved control of blood glucose, blood pressure, and lipids; and earlier diagnosis, partly from informal screening. (A recent study using British general practice data found that one-third of people aged over 40 years [excluding those known to have diabetes] underwent blood glucose measurement in the previous 2 years.)

The debate on whether there should be organised screening has shifted towards a broad-based approach of cardiovascular risk reduction. This is logical, as the main risk for those with undiagnosed type 2 diabetes is vascular disease. The arguments for screening are that:

- Many people with type 2 diabetes, perhaps 20% although some estimates are higher, are undiagnosed.
- People can develop complications such as eye disease, before they develop symptoms and have their diabetes diagnosed.
- The risk of heart disease is increased, and the first symptom of heart disease may be a heart attack which is often fatal.
- People with impaired glucose tolerance (IGT) are also at higher risk of heart disease than those with normal glucose levels.
- Progression to diabetes can be reduced or delayed by lifestyle measures (and by drug therapy, such as metformin).

So the aim of screening would be to treat hyperglycaemia and the vascular risk at an early stage, and to prevent complications.

There is then the additional debate about whom to screen. Consensus exists on the need for selective screening, by age and risk factors. For practical purposes (given that screening would be done in primary care), the other factors would be those which are firstly, recorded in GP records, and secondly, are strongly predictive of diabetes or ‘pre-diabetes’. So screening might be based on: age over 40 years; body mass index (BMI) over 26 kg/m²; presence of other markers of metabolic disease such as hypertension, high cholesterol or triglycerides, ischaemic heart disease, or peripheral arterial disease; and, if available, family history of diabetes or other metabolic disease. In reality, age and BMI provide a good basis for selection.

If we did have organised screening, we would, depending on the test used and the cut-offs chosen, detect more people with lesser degrees of glucose impairment, such as IGT, than with undiagnosed diabetes. Macrae and colleagues screened high-risk patients and found 8.5% to have type 2 diabetes and 9.6% to have IGT or impaired fasting glycaemia. In the wider population, there are probably about three times as many people with IGT as with type 2 diabetes. Non-pharmacological interventions with diet and physical activity have been shown to be effective in large trials in Finland, the US, India, and China. But these trials involved volunteers in whom compliance is likely to be much better than average, and even in them compliance waned over time, despite continued intervention. In other studies, once the intervention stopped, the effect was soon lost.

The duration of many trials is far too short
I think a key question for governments in addressing the rise in type 2 diabetes and its precursors, is the balance between the ‘medical model’ (screening and health care interventions) and public health measures. This was raised in a survey of GPs and practice nurses’ views by Rhys Williams and colleagues.12 One practice nurse responded that asking primary care staff to take on the identification and management of patients with IGT and impaired fasting glucose ‘almost medicalises something which is actually a social problem’.

In theory, we could prevent most cases of type 2 diabetes if we could persuade the population to be more active and keep to an ideal weight. We don’t seem to be succeeding at present.

A key issue for the government is how to deal with unhealthy lifestyles: whether to assume failure and apply medical measures, such as screening and drug treatment, or seek to combat the rising prevalences of obesity and diabetes by government action. Health education does not seem to work, so perhaps tougher measures are needed, along with evaluation of current methods. There could be many options for government, but some would be unpopular with the electors, and are unlikely to be adopted by politicians. Government actions could include:

- Being much tougher on food manufacturers: a tax on the saturated fat, salt and sugar contents of food.
- Encouraging physical activity: cycle lanes completely separate from other road traffic would be a good start. Better lighting and other ways of making streets safer to walk in might also help.
- Increasing the tax on alcoholic drinks: the greatest harm done by alcoholic drinks may be from calories rather than alcohol.
- Encouraging personal responsibility for health by financial incentives or disincentives: perhaps people with high BMIs should pay for prescriptions for diabetes drugs and statins.
- Encouraging government employees, especially those in direct contact with patients, to take responsibility for their health so that they set good examples.

It would be difficult for any government to propose such strategies, and most would be unlikely to gain widespread support. There is a tension between people’s right to choose their own lifestyles, and the impact that those lifestyles have on NHS costs, and hence the opportunity costs to other people who will be deprived of some other form of health care. But in the absence of an effective public health strategy, the prevalences of obesity and diabetes will rise further, with inevitable consequences in terms of morbidity, mortality, workload, and costs.

Norman Waugh,
Department of Public Health, University of Aberdeen.

REFERENCES


DOI: 10.3399/bjgp08X319693

ADDRESS FOR CORRESPONDENCE

Norman Waugh
Department of Public Health, Medical School Buildings, Foresterhill, Aberdeen AB25 2ZD
E-mail: N.R.Waugh@abdn.ac.uk